logo
Plus   Neg
Share
Email

Stock Alert: Dynavax Technologies Up 40% On COVID-19 Vaccine News

Shares of the small-cap biotech Dynavax Technologies Corp. (DVAX) surged over 40% on Tuesday morning after the company said it expects one or more of its collaboration partners in the development of a COVID-19 vaccine to begin a Phase 1 clinical trial as soon as July.

DVAX is currently trading at $6.86, up $2.00 or 41.26%, on the Nasdaq.

The company says it plans to provide an update on its early-stage collaborations in meetings with analysts and investors today.

Dynavax has made available its proprietary toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018TM, for the development of effective vaccines against COVID-19. CpG 1018 is the adjuvant used in HEPLISAV-B, an adult hepatitis B vaccine approved by the US FDA.

Meanwhile, Moderna, Inc. (MRNA) yesterday announced positive clinical results from the phase I study of its vaccine candidate, mRNA-1273, against coronavirus. The vaccine produced protective antibody in a small group of people, who participated in the study.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020. Walmart announced its decision to raise wages for around 165,000 hourly associates across all its U.S. stores starting October, and introduce a team-based operating model in Supercenters. In a tweet, the retail giant said, "Today we're introducing new leadership roles and cross-training opportunities, giving our associates more ways to grow their careers."
Follow RTT